106 related articles for article (PubMed ID: 27432558)
1. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
[TBL] [Abstract][Full Text] [Related]
2. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
4. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell.
Zhang D; Ma Q; Shen S; Hu H
Pancreas; 2009 Jan; 38(1):94-100. PubMed ID: 19106745
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
[TBL] [Abstract][Full Text] [Related]
8. Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.
Zhou C; Chen X; Zeng W; Peng C; Huang G; Li X; Ouyang Z; Luo Y; Xu X; Xu B; Wang W; He R; Zhang X; Zhang L; Liu J; Knepper TC; He Y; McLeod HL
Oncotarget; 2016 Oct; 7(42):68314-68327. PubMed ID: 27582542
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer.
Wagner M; Wuest M; Lopez-Campistrous A; Glubrecht D; Dufour J; Jans HS; Wuest F; McMullen TPW
Endocr Relat Cancer; 2020 Sep; 27(9):495-507. PubMed ID: 32590338
[TBL] [Abstract][Full Text] [Related]
10. Afamin promotes glucose metabolism in papillary thyroid carcinoma.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Luo QY
Mol Cell Endocrinol; 2016 Oct; 434():108-15. PubMed ID: 27329154
[TBL] [Abstract][Full Text] [Related]
11. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice.
Lin X; Luo K; Lv Z; Huang J
Hepatogastroenterology; 2012; 59(114):584-8. PubMed ID: 22353526
[TBL] [Abstract][Full Text] [Related]
12. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
14. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Ball DW; Jin N; Xue P; Bhan S; Ahmed SR; Rosen DM; Schayowitz A; Clark DP; Nelkin BD
Oncol Rep; 2015 Nov; 34(5):2319-24. PubMed ID: 26324075
[TBL] [Abstract][Full Text] [Related]
15. Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells.
Plante MK; Arscott WT; Folsom JB; Tighe SW; Dempsey RJ; Wesley UV
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):16-22. PubMed ID: 22986577
[TBL] [Abstract][Full Text] [Related]
16. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
[TBL] [Abstract][Full Text] [Related]
18. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation.
Munabi NC; England RW; Edwards AK; Kitajewski AA; Tan QK; Weinstein A; Kung JE; Wilcox M; Kitajewski JK; Shawber CJ; Wu JK
Stem Cells Transl Med; 2016 Jan; 5(1):45-55. PubMed ID: 26574555
[TBL] [Abstract][Full Text] [Related]
19. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]